Sec Form 3 Filing - Quinlan Amy @ Voyager Therapeutics, Inc. - 2026-05-08

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Quinlan Amy 2. Issuer Name and Ticker or Trading Symbol Voyager Therapeutics, Inc. [ VYGR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Principal Accounting Officer (Last) (First) (Middle) C/O VOYAGER THERAPEUTICS, INC.,, 75 HAYDEN AVENUE 3. Date of Earliest Transaction (MM/DD/YY) 05/08/2026 (Street) LEXINGTON, MA02421 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 36,749 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 5.28 ( 2 ) 01/13/2035 Common Stock 50,000 D Stock Option (Right to Buy) $ 3.68 ( 3 ) 02/06/2036 Common Stock 28,500 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Quinlan Amy C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE LEXINGTON, MA02421 Principal Accounting Officer Signatures /s/ Gregory L. Shiferman, as Attorney-in-Fact for Amy Quinlan 05/18/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes shares of common stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "2015 Plan") and the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan") that vest periodically. Each RSU represents the right to receive one share of common stock upon vesting. ( 2 )This stock option was issued pursuant to the 2015 Plan. The vesting commencement date of the option is the grant date, January 13, 2025. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting on the one-year anniversary of the vesting commencement date, and an additional 1/36th of the shares of common stock underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service. ( 3 )This stock option was issued pursuant to the 2025 Plan. The vesting commencement date of the option is the grant date, February 06, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting on the first month anniversary of the vesting commencement date, and an additional 1/48th of shares underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service.

Remarks: Exhibit 24.1: Limited Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.